Oncotelic Therapeutics, Inc.
OTLC
$0.09
$0.000.54%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.30% | 232.46% | 26.91% | 18.36% | -2,966.00% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 268.24% | -34.37% | 2.37% | -98.34% | 105.88% |
| Total Other Non-Cash Items | -83.14% | -499.57% | -132.12% | -11.53% | 1,154.17% |
| Change in Net Operating Assets | 37.93% | 533.74% | -17.50% | 135.09% | -26.16% |
| Cash from Operations | -114.39% | 51.80% | 27.83% | 72.11% | 42.47% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 185.45% | -6.90% | -36.00% | -86.33% | -47.62% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 185.45% | -6.90% | -36.00% | -85.09% | -34.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 317.97% | 107.53% | -137.63% | 35.55% | -10.90% |